CN115335047B - 用于治疗血管脂肪瘤的组合物 - Google Patents

用于治疗血管脂肪瘤的组合物

Info

Publication number
CN115335047B
CN115335047B CN202180025551.1A CN202180025551A CN115335047B CN 115335047 B CN115335047 B CN 115335047B CN 202180025551 A CN202180025551 A CN 202180025551A CN 115335047 B CN115335047 B CN 115335047B
Authority
CN
China
Prior art keywords
pharmaceutical composition
lipoma
vascular
weight
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180025551.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN115335047A (zh
Inventor
艾伦·布鲁门菲尔德
拉凯利·盖塔
伊兰·布劳格伦德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rachel Therapeutics Ltd
Original Assignee
Rachel Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rachel Therapeutics Ltd filed Critical Rachel Therapeutics Ltd
Publication of CN115335047A publication Critical patent/CN115335047A/zh
Application granted granted Critical
Publication of CN115335047B publication Critical patent/CN115335047B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dental Preparations (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Prostheses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
CN202180025551.1A 2020-01-28 2021-01-27 用于治疗血管脂肪瘤的组合物 Active CN115335047B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062966577P 2020-01-28 2020-01-28
US62/966,577 2020-01-28
PCT/IB2021/000035 WO2021152390A1 (en) 2020-01-28 2021-01-27 Compositions for the treatment of angiolipoma

Publications (2)

Publication Number Publication Date
CN115335047A CN115335047A (zh) 2022-11-11
CN115335047B true CN115335047B (zh) 2025-09-19

Family

ID=77078612

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180025551.1A Active CN115335047B (zh) 2020-01-28 2021-01-27 用于治疗血管脂肪瘤的组合物

Country Status (7)

Country Link
US (1) US20230089484A1 (https=)
EP (1) EP4096653A4 (https=)
JP (1) JP7850665B2 (https=)
CN (1) CN115335047B (https=)
AU (1) AU2021213469A1 (https=)
IL (1) IL295014A (https=)
WO (1) WO2021152390A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3307323B1 (en) 2015-06-15 2022-07-13 Raziel Therapeutics Ltd. Carbazole derivatives for the treatment of fibrotic diseases and related symptoms, and conditions thereof
AU2020347539A1 (en) * 2019-09-15 2022-03-31 Raziel Therapeutics Ltd. Compositions for the treatment of solid tumors
JP2024529906A (ja) * 2021-07-28 2024-08-14 ラジエル セラピューティクス エルティーディー． 脂肪腫の疼痛を処置するための組成物および方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104010636A (zh) * 2011-11-15 2014-08-27 耶路撒冷希伯来大学伊森姆研究发展有限公司 三环化合物、包含它们的组合物及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102712601A (zh) * 2009-11-12 2012-10-03 赛尔维他股份公司 化合物、其制备方法、药物组合物、化合物的用途、用于调节或调控丝氨酸/苏氨酸激酶的方法以及丝氨酸/苏氨酸激酶调节剂
RU2020111934A (ru) * 2013-10-08 2020-04-29 Промедиор, Инк. Способы лечения фиброзного рака
EP3060215A4 (en) * 2013-10-21 2017-06-14 Alevere Medical Corporation Fused heterocyclic organic compounds, pharmaceutical compositions, and medical uses thereof
WO2016020919A1 (en) * 2014-08-07 2016-02-11 Raziel Therapeutics Ltd. Compositions comprising tricyclic compounds, and uses thereof
EP3307323B1 (en) 2015-06-15 2022-07-13 Raziel Therapeutics Ltd. Carbazole derivatives for the treatment of fibrotic diseases and related symptoms, and conditions thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104010636A (zh) * 2011-11-15 2014-08-27 耶路撒冷希伯来大学伊森姆研究发展有限公司 三环化合物、包含它们的组合物及其用途

Also Published As

Publication number Publication date
IL295014A (en) 2022-09-01
EP4096653A4 (en) 2024-02-28
EP4096653A1 (en) 2022-12-07
JP7850665B2 (ja) 2026-04-23
WO2021152390A1 (en) 2021-08-05
US20230089484A1 (en) 2023-03-23
JP2023510865A (ja) 2023-03-15
CN115335047A (zh) 2022-11-11
AU2021213469A1 (en) 2022-08-25

Similar Documents

Publication Publication Date Title
CN115335047B (zh) 用于治疗血管脂肪瘤的组合物
US20090082400A1 (en) Soluble pyrone analogs methods and compositions
US20090325906A1 (en) Methods and compositions for therapeutic treatment
KR19980081621A (ko) 과민성 장 증후군의 증상을 치료하기 위한 엔케이-1 수용체 길항물질
JP7822308B2 (ja) 固形腫瘍の処置のための組成物
JPH11501282A (ja) コリン受容体作用薬及び拮抗薬としてのエピバチジン及びその誘導体
ES2928666T3 (es) Piridinetionas, sus composiciones farmacéuticas y su uso terapéutico para el tratamiento de enfermedades proliferativas, inflamatorias, neurodegenerativas o inmunomediadas
EP4149941B1 (en) Certain chemical compositions and methods of use thereof
EP3816166A1 (en) Tlr7 agonist and pharmaceutical combination thereof for treating lung cancer
JP2024506228A (ja) 脂質関連障害の処置のための組成物および方法
US20240041827A1 (en) Compositions for the treatment of fat related conditions and disorders
US20240335424A1 (en) Compositions and methods for treating lipoma pain
SG11202111960PA (en) Method for treating endometriosis-associated pain by using diaminopyrimidine compound
EP3960179B1 (en) Method for treating cough by using diaminopyrimidine compound
HK40077772A (en) Compositions for the treatment of solid tumors
US20210221817A1 (en) Novel heteroaromatic compounds as potent modulators of the hippo-yap signaling pathway lats1/2 kinases
KR20040007476A (ko) 방광 과민증 치료제
CN113164487B (zh) 磷酸二酯酶抑制剂
WO1994018974A1 (en) (+)- 2-methylpiperidine as modulator of cholinergic systems
CN116217567A (zh) 烃基取代的α-咔啉类似物或其药用盐、其药物组合物及其制备方法和用途
HK40044357A (en) Tlr7 agonist and pharmaceutical combination thereof for treating lung cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant